Background/Aim Herbal and dietary supplement (HDS) hepatotoxicity is increasingly being reported in the USA. This case series describes the presenting clinical features and outcomes of seven patients with liver injury attributed to OxyELITE Pro enrolled in the Drug-Induced Liver Injury Network (DILIN) study. Methods The 6-month outcomes of patients with hepatotoxicity attributed to OxyELITE Pro enrolled in the DILIN prospective registry between 2004 and 2015 are presented. Results Six of the seven patients (86 %) presented in 2013 with symptoms of hepatitis and acute hepatocellular injury.
Introduction
An estimated 50-60 % of adult Americans ingest an herbal or dietary supplement (HDS) on a regular basis for a variety of touted health benefits [1, 2] . Although HDS products are perceived to be safe and ''natural'', they do not undergo routine efficacy or safety testing. A recent study reported that at least 23,000 emergency department visits in the USA each year are attributed to adverse events from dietary supplements [3] . Despite this, the Food and Drug Administration (FDA) has limited authority to regulate the manufacturing and content of HDS products [4] .
OxyELITE Pro (USP Labs, Dallas, TX) is a multi-ingredient nutritional supplement used by many individuals as a weight loss and energy-enhancing aid [5] . In mid-to late 2013, over 40 cases of severe acute hepatitis and liver failure were linked to the use of the ''Super Thermo'' formulation of OxyELITE Pro, primarily among individuals residing in Hawaii [5] [6] [7] [8] . The etiology and risk factors for hepatotoxicity among these patients remain under investigation. However, the sudden outbreak followed shortly after a major modification of the components of OxyELITE Pro with the addition of aegeline, a constituent of the native Ayurvedic herbal product made from the bark of the bael tree (Aele marmelos). The product added to OxyELITE Pro, however, had been synthesized by a manufacturer in China, and its purity, safety and relationship to the natural herbal product was not clear.
Before, during and after the outbreak of liver injury attributed to OxyELITE Pro, the Drug-Induced Liver Injury Network (DILIN) had been conducting a prospective multicenter study of the etiologies and outcomes of patients who developed liver injury due to ingestion of drugs and HDS products in the USA [9, 10] . Over the course of DILIN study, the proportion of cases attributed to various HDS products including body-building agents and weightloss products increased markedly, from 7 % in 2004-2006 to 20 % since 2012 [11] . Among the 246 adjudicated cases of DILI attributed to HDS products, seven were considered to be due to OxyELITE Pro, six of which presented during mid-to late 2013. The aim of the current study was to describe the presenting features, clinical course and outcomes of seven patients enrolled in the DILIN prospective study with liver injury attributed to OxyELITE Pro.
Methods

DILIN Prospective Study
The protocol for this multicenter observational study was approved by the Institutional Review Boards at each clinical site and all enrolled subjects provided written informed consent. Liver injury onset was defined as the first date after a subject taking any medication or HDS product met the predefined laboratory criteria for study entry. Specifically, all subjects had to meet one of the following laboratory criteria on two consecutive blood draws: (1) a serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level that exceeded five times the upper limit of normal (ULN) (or five times a pretreatment baseline value if abnormal); (2) a serum alkaline phosphatase (Alk P) that exceeded two times the ULN (or two times the pretreatment value if abnormal); or (3) a total bilirubin of 2.5 mg/dL or greater, or an international normalized ratio (INR) greater than 1.5 accompanied by an enzyme elevation. To qualify for enrollment, study participants had to be enrolled within 6 months of onset.
A detailed medical history was obtained at the enrollment study visit, and medical records were retrieved and relevant information was extracted. Additional laboratory and radiological testing were performed if necessary to more fully characterize the event and exclude competing etiologies. Specifically, testing for hepatitis A, B, C, HIV, autoantibodies, CMV, and EBV infection was obtained in all subjects and serum was stored in a sample repository for future diagnostic testing and ancillary studies. In this regard, available samples were later tested for IgG anti-HEV and, if positive, for IgM anti-HEV as previously reported [12] . All enrolled patients were asked to return for a follow-up visit at 6 months after enrollment, and those with persistent evidence of liver injury at 6 months after onset were then asked to return at 12 and 24 months.
The causal relationship between the liver injury episode and the implicated agent(s) was evaluated in a standardized fashion by the DILIN Causality Committee [13] . A DILIN expert opinion causality score varying from 1 (definite C95 % likelihood), 2 (highly likely 75-94 % likelihood), 3 (probable 50-74 % likelihood), 4 (possible 25-49 % likelihood) to 5 (unlikely \25 % likelihood) was assigned by consensus agreement of committee members. In addition, an updated causality score using the standardized Roussel Uclaf Causality Assessment Method (RUCAM) was calculated for each case and implicated agent by manuscript authors in 2015 [14] . By convention, RUCAM scores are grouped into likelihood levels as ''excluded'' (B0), ''unlikely'' [1, 2] , ''possible'' [3] [4] [5] , ''probable'' [6] [7] [8] and ''highly probable'' ([8) . In subjects with two or more implicated drugs or HDS products, an overall causality score was assigned to the case and then a causality score was also determined for each individual suspect drug or HDS product.
The pattern of liver injury was categorized based upon the R ratio which was defined by the formula: [ALT/ULN]/ [Alk P/ULN]. Cases were considered hepatocellular if R [ 5, cholestatic if R \ 2 and mixed if R 2-5. The severity of the DILI episode was categorized on a 5-point scale from mild [1] , moderate [2] , moderate-hospitalized [3] , severe [4] , and fatal [5] , where a fatal score was assigned only if the patient died or underwent liver transplantation due to DILI within 6 months of onset [8] .
Liver Histopathology
Liver biopsy was not required and was not a component of the DILIN Prospective Study protocol, but if a biopsy were done as a part of clinical evaluation and care, a request was made for slides to be forwarded to the Laboratory of Pathology, NIH. All available specimens were reviewed by a single expert liver histopathologist (DEK) and scored for multiple histological features as well as an overall pattern of liver injury as previously described [15] .
Data Collection and Statistics
Electronic case report forms (eCRFs) via InForm TM (Oracle Health Solutions, CA) were used to capture data in the DILIN prospective study. Data reported here were based on the data download from InForm TM in December 2015. Summary statistics were reported as median with range for continuous data and frequency with percentage for categorical data. SAS 9.4 [SAS Institute, Cary, NC] was used for all statistical analyses.
Results
Between 2004 and 2015, 1596 patients were enrolled in the DILIN prospective study, seven of whom (0.5 %) had liver injury attributed to OxyELITE Pro. One case had injury onset in 2011 and the remaining six occurred between May and December 2013. These seven cases represented 2.8 % of the 246 adjudicated cases attributed to HDS products and 5.3 % of the cases enrolled during calendar year 2013.
The demographic, clinical and laboratory features of the seven patients with liver injury attributed to OxyELITE Pro are summarized in Table 1 . All seven patients were adults, the median age was 36 years (range 28-62), and 6 (86 %) were women. Self-reported race and ethnicity indicated that 4 were Caucasian (one being Hispanic) and 3 Asian. While the most common reason for taking OxyELITE Pro was weight loss, most patients had a normal body mass index, one being mildly overweight and only one obese. The median duration of OxyELITE Pro use before liver injury onset was 18 weeks, but ranged from 5 to 102 weeks. Two patients reported taking OxyELITE Pro in the past (before 2013) without ill effects and one patient took the product for 2 years but presented with liver injury 6 months after March 2013 when the product was modified. Only one patient was a moderate drinker, and none had a history of alcohol abuse or obvious risk factors for viral hepatitis.
On clinical presentation, the pattern of serum enzyme elevations was hepatocellular in all patients; the median R ratio being 16 (range 11-107) . Initial ALT values were above 1000 U/L in five patients and averaged 2950 U/L. Initial Alk P values in contrast were typically normal (n = 2) or only modestly elevated (n = 5) in the range of 1.5-3 times ULN. Serum total bilirubin values were raised in six patients and ranged widely (0.4 to 24.5 mg/dL) and averaged 10.9 mg/dL. Immunoallergic features were not prominent; one patient had rash, two had fever, and none had documented peripheral eosinophilia. Autoantibodies were present in four patients but none had other features of autoimmune hepatitis and corticosteroids were used in only one patient, who had rapidly progressive hepatic failure. Testing for acute HAV, HBV and HCV infection was negative in all patients, although one (case #7) appeared to be a chronic carrier of hepatitis B who had a superimposed severe acute liver injury (having HBsAg without IgM antiHBc and no detectable HBV DNA). Tests for acute HEV infection were available on seven patients and were negative in all. Liver imaging was performed in all patients, and none had evidence of biliary obstruction or hepatic masses.
Causality Assessment
Formal causality assessment judged 1 case to be definite, 2 highly likely, 3 probable, and 1 possible liver injury due to exposure to OxyELITE Pro (Table 1) . Similarly, the RUCAM scores varied from 2 to 7, being in the range of unlikely in 1, possible in 4 and probable in 2 (calculations are shown in Supplementary Table 1) . Five patients were taking other prescription medications or HDS products that were listed as implicated, but only in case #1 were these agents considered a more probable cause of the hepatic injury.
Clinical Severity and Outcomes
The DILIN severity scores included 1 mild, 3 moderatehospitalized, 1 severe and 2 fatal, the latter two undergoing emergency liver transplantation 24 days after clinical presentation. Liver histology was available for central review in three patients. One patient (case #2) with a percutaneous liver biopsy done 4 days after presentation and at the peak of injury showed a cholestatic hepatitis pattern best characterized as acute hepatitis with moderate, predominantly lobular inflammation, mild canalicular cholestasis, and scattered eosinophils (Fig. 1a, b) . Recuts from a single paraffin block from each of the two explants were also available for review (Fig. 1c, d ). One case showed 
Azithromycin (4) Ravage (4) Hydroxycut (5 submassive necrosis with few residual viable hepatocytes, while the other showed necrosis in zone 1 and 3 with extensive bridging necrosis and early regenerative nodule formation. Although plasma cells were noted within the infiltrate at transplantation, neither had other features suggestive of autoimmune hepatitis. The residual parenchyma in both cases showed prominent cholestasis. At last follow-up, at 22 and 26 months post-transplant, the two patients who underwent liver transplantation were doing well and had normal serum bilirubin and liver enzymes. Four of the other five patients had self-limited hepatitis with full recovery without corticosteroid or other specific therapy at month 6 but one patient (case #4) had evidence of mild biochemical liver injury at follow-up month 8.
Discussion
These seven generally healthy, middle aged adults developed acute hepatitis after ingesting a widely used weight loss, multi-ingredient nutritional product called OxyELITE Pro for as short as 5 weeks to as long as 2 years. Outcomes were generally severe with six patients jaundiced and hospitalized, three developing acute liver failure, and two requiring emergency liver transplantation. Six of the seven patients had taken OxyELITE Pro in mid-to-late 2013 which was the period that the reformulated Super Thermo formulation of OxyELITE Pro had been marketed and distributed. In all cases, the daily dose of OxyELITE Pro ingested was within the recommendations from the manufacturer. Interestingly, three patients had taken other OxyELITE Pro formulations without adverse consequences in the past, prior to 2013. Indeed, the long latency to onset in two patients (case #4 and #5) may have been the result of taking OxyELITE Pro produced before 2013, when the constituents did not include aegeline and switching to the reformulated product in 2013. Evaluation for competing causes of liver injury was unrevealing in all except case #7 who presumably had pre-existing chronic HBV infection. The histological pattern of liver injury from four cases was compatible with other reports of toxin-or drug-mediated liver injury. Submassive hepatic necrosis is usually due to drugs and or ischemia. In these cases, the pattern of necrosis and inflammation was not compatible with an ischemic etiology. In contrast to cases of acute liver failure ascribed to autoimmune hepatitis, there were no lymphoid aggregates and the infiltrate was not rich in plasma cells [16] . Similarly, a mixed pattern of hepatitis and cholestatic features as noted in case #1 is typical of drug hepatotoxicity and is not characteristic of autoimmune hepatitis [15, 17] . While four of the patients described here had detectable autoantibodies at the onset of illness, liver histology was generally not consistent with autoimmune hepatitis. In addition, none had evidence of hypergammaglobulinemia at presentation nor during follow-up, and four of the five who survived without liver transplantation had normal liver enzymes in follow-up and were never treated with corticosteroids. Thus, the presence of low and moderate autoantibody reactivity in these patients was probably due to the severity of the acute liver injury rather than as an indication of autoimmune liver disease.
OxyELITE Pro is a product that contains a number of vitamins, herbs, and other micronutrients and compounds. The Super Thermo OxyELITE Pro product was reformulated in April 2013, at the request of the US FDA, to remove the ingredient 1,3-dimethylamylamine (DMAA), which had been linked to cardiovascular toxicity [8, 18] . Chemical analysis of the Super Thermo formulation of OxyELITE Pro linked to cases of hepatotoxicity has demonstrated the presence of aegeline (N-(2-hydroxy-2(4-methoxyphenyl)ethyl)-3-phenyl-2-propenamide). This compound can be extracted from Aegle marmelos (bael leafs) which has a long history of use in Ayurvedic medicine to improve ''energy levels''. It has been alleged that the aegeline in the Super Thermo formulation of OxyE-LITE Pro was chemically synthesized, and the possibility exists that the product included metabolic intermediates or was a racemic mixture with one isomer having hepatotoxic potential [19] . Although rare published reports have suggested occasional adverse effects from aegeline consumption, the mechanism by which aegeline and/or other components of OxyELITE Pro might mediate liver damage is unknown. OxyELITE Pro also contains green tea extract, which has been linked to recent reports of severe hepatotoxicity in humans [20, 21] . However, the amount of green tea extract is limited and there was no apparent relationship between the daily dose of OxyELITE Pro taken and severity of liver injury, either in this series or in those reported by the CDC or by observers in Honolulu. Nonetheless, recent weight loss could lower the threshold for inadvertent liver toxicity from catechins in green tea extract as was recently demonstrated in animal studies [4, 22, 23] .
The US FDA enjoined USP Labs to cease marketing and distribution of the Super Thermo formulation of [7] . Firstly, the median age of the patients was similar (36 vs 33 years) and there was an over-representation of individuals of east Asian descent compared to the general US population (43 and 80 vs 5.5 %) raising the possibility of a genetic predilection to hepatotoxicity from this HDS product, as has been reported with other drugs [24, 25] . In addition, most patients presented with severe acute hepatocellular injury after several months of OxyELITE Pro ingestion and all but one patient in the current series presented between April and November 2013 (Table 1) . However, all of the DILIN cases occurred in the continental US in comparison with the larger outbreak that was reported primarily in Hawaii. An investigation of the Hawaii cases failed to demonstrate a common batch or expiration date of the OxyELITE Pro product that was consumed [26] . The DILIN cases tended to have more severe outcomes, including a higher rate of hospitalization (86 vs. 38 %) and liver transplant or death (29 vs. 10 %) , which may relate to ascertainment and/or referral bias. Autoimmune features were present in both series, although none from the current study had prominent autoimmune features.
Limitations of the current study include the small number of cases limiting the ability to identify risk factors for liver injury. In addition, we were not able to obtain a sample of the actual OxyELITE Pro formulation ingested for formal chemical analysis of potential hepatotoxic ingredients or adulterants as have been found in other HDS products [27] . Likewise, we could not confirm that the patients were taking the Super Thermo formulation, although the timing was suggestive in six of the seven cases. Another potential confounding factor was that several of the patients were taking other HDS products that have been associated with hepatotoxicity [28] [29] [30] but only in case #1 were these other products thought to be even probably related.
The outbreak of severe acute hepatitis due to OxyELITE Pro was striking and led quickly to the identification of the responsible agent. At the same time, there has been a gradually increasing rate of liver injury from HDS products reported largely due to multi-ingredient products similar to OxyELITE Pro that contain multiple vitamins, minerals, nutritional elements and herbal products or synthetic compounds. The components of the typical multi-ingredient dietary supplements often change and their purity and reliability are not well documented. These findings stress the importance of considering HDS products in assessing acute liver injury of unknown cause, reporting such incidents (to Medwatch if possible) and attempting to obtain the suspect product for chemical analysis. These findings also indicate a need for enhanced regulatory actions in monitoring the commercial availability of these widely used weight-loss products.
